Priya Gopal with Novartis to Speak at the Knowledge Group’s Drug Supply Chain Security Act

KC-Events's picture
Printer-friendly versionPrinter-friendly versionPDF versionPDF version

Priya Gopal, Associate Director, Strategic Planning and Projects, Novartis to Speak at the Knowledge Group’s Exploring the Drug Supply Chain Security Act (DSCSA) and its Impact to Drug Manufacturers, Wholesalers, and Pharmacies LIVE Webcast. Please refer to the below for more information.


New York City, United States, June 5, 2014 - (PressReleasePoint) - The Knowledge Group/The Knowledge Congress Live Webcast Series, the leading producer of regulatory focused webcasts, has announced today that Priya Gopal, Associate Director, Strategic Planning and Projects, Novartis will speak at the Knowledge Group’s webcast entitled: “Exploring the Drug Supply Chain Security Act (DSCSA) and its Impact to Drug Manufacturers, Wholesalers, and Pharmacies.”  This event is scheduled for August 11, 2014 from 12:00pm – 2:00pm (ET).

For further details, please visit:  http://theknowledgegroup.org/event_name/the-drug-quality-and-security-act-hr-3204-implications-for-drug-manufacturerspharmacies-and-healthcare-live-webcast/  

About Priya Gopal

Priya Gopal is a Associate Director, Strategic Planning and Projects for Novartis .  She is a program manager for serialization and product tracking for Novartis , US.  She has been with Novartis for more than ten years playing various global roles in strategic planning and in program management. Priya was one of the key players in integrating of newly acquired companies Nektar and Chiron to Novartis. Priya has US lead for global wide supply chain optimization program.

Priya has her MBA in finance and is a board member of PDSA (Pharma drug security alliance)

Event Synopsis:

On November 2013, President Obama signed into law The Drug Quality and Security Act (DQSA), which includes in Title II the Drug Supply Chain Security Act (DSCSA).   DSCSA authorizes the Food and Drug Administration (FDA) to develop a track-and-trace system to protect the public from counterfeit, adulterated, and diverted products. The law replaces State level e-Pedigree regulations.

Title I of  DQSA establishes  Food and Drug Administration (FDA) over-sight of drug compounding under Section 503A of the Food, Drug and Cosmetic Act (FD&C) and creates a new section, 503B, that provides over-sight of a new class of manufacturers – large compounding entities called ‘outsourcing facilities.’ These entities will be subject to FDA registration, regulation, and reporting requirements (list of products compounded, active ingredients, and adverse effects).

This law comes in response to a meningitis outbreak attributed to tainted steroid injections that caused 64 deaths and sickened hundreds in 2012.

Title II of DQSA known as DSCSA paves the way for an electronic tracking system to prevent counterfeited or stolen prescription drugs from entering the U.S. Within four years, drug manufacturers will have to include serial numbers on all drug packages and, within 10 years,  to track serialized medicines from manufacturing facilities to pharmacies. Pharmaceutical wholesale licensing standards, transaction verification, and lot -level tracking, requirements come into effect as early as Jan 1, 2015.

About The Knowledge Group, LLC/The Knowledge Congress Live Webcast Series

The Knowledge Group, LLC  was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register to an event, please visit: http://theknowledgegroup.org/    



 


Press Contact:
PR - The Knowledge Group,
123 Town Square Place, Suite 242 Jersey City, NJ 07310
1.800.578.4370
http://www.knowledgecongress.org
********@**o**e**e**n**e**.org
Email partially hidden to block spam. Please use the contact form here.
Contact PR - The Knowledge Group,
Email the contact person for this press release. Do not send spam or irrelevant message.
12 + 4 =


Copy this html code to your website/blog to embed this press release.

Comments

Post new comment

1 + 1 =